Summary
Abbott Laboratories (ABT) filed an 8-K on May 10, 2006, to report a material definitive agreement related to a significant debt issuance. The company entered into an Underwriting Agreement and a Pricing Agreement to issue a total of $4 billion in senior notes across three tranches: $500 million of 5.375% Notes due May 15, 2009, $1.5 billion of 5.600% Notes due May 15, 2011, and $2 billion of 5.875% Notes due May 15, 2016. This substantial debt offering was registered under a previously filed Form S-3 and indicates Abbott's strategy to raise capital, likely for ongoing operations, acquisitions, or other corporate initiatives. The filing also lists various exhibits, including the underwriting and pricing agreements, forms of the notes, and legal opinions, underscoring the structured nature of this financing. Investors should note that while this 8-K details the debt issuance itself, it does not provide specific details on the intended use of the proceeds or current financial performance, which would typically be found in other SEC filings like quarterly earnings reports. The filing was signed by Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer.
Key Highlights
- 1Abbott Laboratories issued $4 billion in senior notes through an Underwriting Agreement and Pricing Agreement.
- 2The debt issuance comprises three tranches: $500 million (5.375% due 2009), $1.5 billion (5.600% due 2011), and $2 billion (5.875% due 2016).
- 3This is a public offering of debt securities registered under a prior Form S-3 filing.
- 4The agreements were dated May 9, 2006.
- 5Key underwriters include ABN AMRO Incorporated, Banc of America Securities LLC, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated.
- 6The filing was made on May 10, 2006, with an event date of May 8, 2006.
- 7Thomas C. Freyman, EVP, Finance and CFO, signed the report.